Search Results for "1"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for 1. Results 871 to 880 of 2588 total matches.
Booster Doses of COVID-19 Vaccines
The Medical Letter on Drugs and Therapeutics • Nov 29, 2021 (Issue 1638)
adult (see Table 1).1,2
DOSAGE — The booster dose is the same as the dose
for primary immunization ...
The FDA has expanded the Emergency Use Authorizations
(EUAs) for the mRNA-based COVID-19 vaccines
manufactured by Pfizer/BioNTech (Comirnaty) and
Moderna (Spikevax) and the adenovirus-based vaccine
manufactured by Johnson & Johnson/Janssen to
include administration of a booster dose in select
populations after primary immunization with either the
same COVID-19 vaccine or a different one.
Exenatide (Byetta) for Type 2 Diabetes
The Medical Letter on Drugs and Therapeutics • Jun 06, 2005 (Issue 1210)
. Glucagon-like
peptide-1 (GLP-1) is one of these. Exenatide is a
GLP-1 agonist (incretin mimetic ...
Exenatide injection (Byetta - Amylin/Lilly), a synthetic peptide that stimulates release of insulin from pancreatic beta cells, has been approved by the FDA as adjunctive therapy for patients with type 2 diabetes who have not achieved optimal glycemic control on metformin (Glucophage, and others), a sulfonylurea, such as glyburide (DiaBeta, and others), or both. Exenatide is not indicated for use with insulin.
Rosiglitazone/Glimepiride (Avandaryl) for Diabetes
The Medical Letter on Drugs and Therapeutics • Mar 13, 2006 (Issue 1230)
(Avandamet).
1
Most patients with type 2 diabetes eventually require 2
drugs with different mechanisms ...
Avandaryl, a new fixed-dose tablet combining the thiazolidinedione rosiglitazone (Avandia) and the sulfonylurea glimepiride (Amaryl, and others), was recently approved by the FDA for treatment of type 2 diabetes. It is approved for patients already taking a combination of rosiglitazone and a sulfonylurea or those not adequately controlled on rosiglitazone or sulfonylurea monotherapy. Rosiglitazone is also available in a fixed-dose combination with metformin (Avandamet). Most patients with type 2 diabetes eventually require 2 drugs with different mechanisms to control...
Omadacycline (Nuzyra) - A New Tetracycline Antibiotic
The Medical Letter on Drugs and Therapeutics • May 20, 2019 (Issue 1572)
to
tetracyclines.
Pronunciation Key
Omadacycline: oh mad" a sye' kleen Nuzyra: new zye' rah
Table 1 ...
The FDA has approved omadacycline (Nuzyra – Paratek),
a semisynthetic tetracycline derivative, for once-daily
IV and oral treatment of community-acquired bacterial
pneumonia (CAP) and acute bacterial skin and skin
structure infections (ABSSSIs) in adults.
Romosozumab (Evenity) for Postmenopausal Osteoporosis
The Medical Letter on Drugs and Therapeutics • Jun 03, 2019 (Issue 1573)
(Tymlos) and teriparatide
(Forteo) were approved earlier.1 Other drugs used for
treatment ...
The FDA has approved romosozumab-aqqg (Evenity –
Amgen), a sclerostin inhibitor, for once-monthly
subcutaneous (SC) treatment of osteoporosis in
postmenopausal women who are at high risk
for fracture (history of osteoporotic fracture or
multiple risk factors for fracture) or who have failed
or cannot tolerate other drugs for this indication.
Romosozumab is the first sclerostin inhibitor to be
approved in the US and the third drug for treatment of
postmenopausal osteoporosis that stimulates bone
formation; the parathyroid hormone (PTH) receptor
agonists abaloparatide (Tymlos) and...
Drugs for Hypertriglyceridemia
The Medical Letter on Drugs and Therapeutics • Mar 04, 2013 (Issue 1411)
triglyceride levels and should be tried first.1-3
TRIGLYCERIDE LEVELS AND RISK — Mildly (150-
200 mg/dL ...
Fibrates, niacin and fish oil are promoted for treatment
of hypertriglyceridemia. HMG-CoA reductase inhibitors
(statins) can lower elevated serum concentrations of
triglycerides, but less so than fibrates, niacins or fish oil.
Lifestyle changes such as weight reduction, exercise
and decreasing alcohol intake can also lower serum
triglyceride levels and should be tried first.
Comparison Table: Triptans for Migraine (online only)
The Medical Letter on Drugs and Therapeutics • Jun 12, 2023 (Issue 1678)
6.25, 12.5 mg tabs
20, 40 mg tabs 2.5 mg tabs 1, 2.5 mg tabs 5, 10 mg tabs, ODTs Imitrex and generics ...
View the Comparison Table: Triptans for Migraine
Med Lett Drugs Ther. 2023 Jun 12;65(1678):e97-9 doi:10.58347/tml.2023.1678b | Show Introduction Hide Introduction
Safe Needles
The Medical Letter on Drugs and Therapeutics • Apr 05, 1991 (Issue 841)
SHEATHING MECHANISMS
Sliding Sleeve
Click Lock ICU Medical (Irvine, CA; 1-800-824-7890) IV catheter ...
Accidental needlesticks can lead to infection with hepatitis viruses, human immunodeficiency virus, and other blood-borne bacterial, viral, and fungal pathogens (DK Henderson et al, Ann Intern Med, 113:740, 1990). Re-capping used needles is the most frequent cause of needlestick injuries (J Jagger et al, N Engl J Med, 319:284, 1988; MH Becker et al, Am J Infect Control, 18:232, 1990).
Lodoxamide for Vernal Keratoconjunctivitis
The Medical Letter on Drugs and Therapeutics • Mar 18, 1994 (Issue 918)
, has been marketed in a 0.1% ophthalmic solution
(Alomide − Alcon) for treatment of vernal keratoconjunctivitis ...
Lodoxamide, a mast cell stabilizer, has been marketed in a 0.1% ophthalmic solution (Alomide - Alcon) for treatment of vernal keratoconjunctivitis.
Rivaroxaban (Xarelto) for Acute Coronary Syndrome
The Medical Letter on Drugs and Therapeutics • Dec 12, 2011 (Issue 1379)
discharge.1 The addition of the oral
anticoagulant warfarin (Coumadin, and others) to dual
antiplatelet ...
The standard antithrombotic therapy for treatment of
patients with acute coronary syndrome (ACS) is dual
antiplatelet therapy with aspirin and clopidogrel (Plavix)
or another thienopyridine, plus a parenteral anticoagulant
while the patient is hospitalized, followed by antiplatelet
therapy alone after discharge. The addition of the oral
anticoagulant warfarin (Coumadin, and others) to dual
antiplatelet therapy is generally not recommended for this
indication because of fluctuations in its anticoagulant
effect and the risk of bleeding. A recently published trial
found that addition of...